The effect of HIV on malaria in the context of the current standard of care for HIV-infected populations in Africa

Future Virology

Volumn 7, Issue 7, 2012, Pages 699-708

  Kamya, Moses R ^a   Byakika Kibwika, Pauline ^a   Gasasira, Anne F ^a   Havlir, Diane ^b   Rosenthal, Philip J ^b   Dorsey, Grant ^b   Achan, Jane ^a  

^a MAKERERE UNIVERSITY   (Uganda)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

antimalarial treatment; antiretroviral therapy; HIV infection; malaria; malaria prevention

Indexed keywords

AMODIAQUINE; AMODIAQUINE PLUS ARTESUNATE; ANTIMALARIAL AGENT; ANTIRETROVIRUS AGENT; ARTEMETHER PLUS BENFLUMETOL; ARTEMISININ; ARTESUNATE; BENFLUMETOL; COTRIMOXAZOLE; DIHYDROARTEMISININ PLUS PIPERAQUINE; EFAVIRENZ; FOLIC ACID ANTAGONIST; INSECTICIDE; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; PYRIMETHAMINE PLUS SULFADOXINE; QUININE; RITONAVIR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AFRICA; ANOREXIA; ANTIMALARIAL DRUG RESISTANCE; ANTIVIRAL THERAPY; BED NET; BLOOD DISEASE; CD4 LYMPHOCYTE COUNT; DNA POLYMORPHISM; DRUG EFFICACY; DRUG ERUPTION; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; GENE MUTATION; HIGH RISK POPULATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; INSECTICIDE RESISTANCE; MALAISE; MALARIA; MALARIA CONTROL; MALARIA FALCIPARUM; PLASMODIUM FALCIPARUM; PREGNANCY; PRIORITY JOURNAL; REVIEW;

EID: 84864452060     PISSN: 17460794     EISSN: 17460808     Source Type: Journal    
DOI: 10.2217/fvl.12.59     Document Type: Review

References (64)

1. Francesconi P, Fabiani M, Dente MG et al. HIV, malaria parasites, and acute febrile episodes in Ugandan adults: A case-control study. AIDS 15(18), 2445-2450 (2001).
2. French N, Nakiyingi J, Lugada E, Watera C, Whitworth JA, Gilks CF. Increasing rates of malarial fever with deteriorating immune status in HIV-1-infected Ugandan adults. AIDS 15(7), 899-906 (2001).
3. Laufer MK, Van Oosterhout JJ, Thesing PC et al. Impact of HIV-associated immunosuppression on malaria infection and disease in Malawi. J. Infect. Dis. 193(6), 872-878 (2006).
4. Whitworth J, Morgan D, Quigley M et al. Effect of HIV-1 and increasing immunosuppression on malaria parasitaemia and clinical episodes in adults in rural Uganda: A cohort study. Lancet 356(9235), 1051-1056 (2000).
5. PatnaikP, Jere CS, Miller WC et al. Effects of HIV-1 serostatus, HIV-1 RNA concentration, and CD4 cell count on the incidence of malaria infection in a cohort of adults in rural Malawi. J. Infect. Dis. 192(6), 984-991 (2005).
6. Ladner J, Leroy V, Simonon A et al. HIV infection, malaria, and pregnancy: A prospective cohort study in Kigali, Rwanda. Am. J. Trop. Med. Hyg. 66(1), 56-60 (2002).
7. Van EijkAM, Ayisi JG, Ter Kuile FO et al. HIV increases the riskof malaria in women of all gravidities in Kisumu, Kenya. AIDS 17(4), 595-603 (2003).
8. Verhoeff FH, Brabin BJ, Hart CA, Chimsuku L, Kazembe P, Broadhead RL. Increased prevalence of malaria in HIV-infected pregnant women and its implications for malaria control. Trop. Med. Int. Health 4(1), 5-12 (1999).
9. Ayisi JG, Van EijkAM, Ter Kuile FO et al. The effect of dual infection with HIV and malaria on pregnancy outcome in western Kenya. AIDS 17(4), 585-594 (2003).
10. Bloland PB, Wirima JJ, Steketee RW, Chilima B, Hightower A, Breman JG. Maternal HIV infection and infant mortality in Malawi: Evidence for increased mortality due to placental malaria infection. AIDS 9(7), 721-726 (1995).
11. Ticconi C, Mapfumo M, Dorrucci M et al. Effect of maternal HIV and malaria infection on pregnancy and perinatal outcome in Zimbabwe. J. Acquir. Immune Defic. Syndr. 34(3), 289-294 (2003).
12. Filler SJ, Kazembe P, Thigpen M et al. Randomized trial of 2-dose versus monthly sulfadoxine-pyrimethamine intermittent preventive treatment for malaria in HIV-positive and HIV-negative pregnant women in Malawi. J. Infect. Dis. 194(3), 286-293 (2006).
13. Chirenda J, Siziya S, Tshimanga M. Association of HIV infection with the development of severe and complicated malaria cases at a rural hospital in Zimbabwe. Cent. Afr. J. Med. 46(1), 5-9 (2000).
14. Cohen C, Karstaedt A, Frean J et al. Increased prevalence of severe malaria in HIV-infected adults in South Africa. Clin. Infect. Dis. 41(11), 1631-1637 (2005).
15. Grimwade K, French N, Mbatha DD, Zungu DD, Dedicoat M, Gilks CF. HIV infection as a cofactor for severe falciparum malaria in adults living in a region of unstable malaria transmission in South Africa. AIDS 18(3), 547-554 (2004).
16. Chalwe V, Van Geertruyden JP, Mukwamataba D et al. Increased riskfor severe malaria in HIV-1-infected adults, Zambia. Emerg. Infect. Dis. 15(5), 749; quiz 858 (2009).
17. Van Geertruyden JP, Mulenga M, Mwananyanda L et al. HIV-1 immune suppression and antimalarial treatment outcome in Zambian adults with uncomplicated malaria. J. Infect. Dis. 194(7), 917-925 (2006).
18. Shah SN, Smith EE, Obonyo CO et al. HIV immunosuppression and antimalarial efficacy: Sulfadoxine-pyrimethamine for the treatment of uncomplicated malaria in HIV-infected adults in Siaya, Kenya. J. Infect. Dis. 194(11), 1519-1528 (2006).
19. Phillips-Howard PA, Nahlen BL, KolczakMS et al. Efficacy of permethrin-treated bed nets in the prevention of mortality in young children in an area of high perennial malaria transmission in western Kenya. Am. J. Trop. Med. Hyg. 68(4 Suppl.), 23-29 (2003).
20. Ter Kuile FO, Terlouw DJ, Kariuki SK et al. Impact of permethrin-treated bed nets on malaria, anemia, and growth in infants in an area of intense perennial malaria transmission in western Kenya. Am. J. Trop. Med. Hyg. 68(4 Suppl.), 68-77 (2003).
21. Ter Kuile FO, Terlouw DJ, Phillips-Howard PA et al. Impact of permethrin-treated bed nets on malaria and all-cause morbidity in young children in an area of intense perennial malaria transmission in western Kenya: Cross-sectional survey. Am. J. Trop. Med. Hyg. 68(4 Suppl.), 100-107 (2003).
22. Kamya MR, Gasasira AF, Achan J et al. Effects of trimethoprim- sulfamethoxazole and insecticide-treated bednets on malaria among HIV-infected Ugandan children. AIDS 21(15), 2059-2066 (2007).
23. Ramphul U, Boase T, Bass C, Okedi LM, Donnelly MJ, Muller P. Insecticide resistance and its association with target-site mutations in natural populations of Anopheles gambiae from eastern Uganda. Trans. R. Soc. Trop. Med. Hyg. 103(11), 1121-1126 (2009).
24. Trape JF, Tall A, Diagne N et al. Malaria morbidity and pyrethroid resistance after the introduction of insecticide-treated bednets and artemisinin-based combination therapies: A longitudinal study. Lancet Infect. Dis. 11(12), 925-932 (2011).
25. Mermin J, Lule J, Ekwaru JP et al. Effect of co-trimoxazole prophylaxis on morbidity, mortality, CD4-cell count, and viral load in HIV infection in rural Uganda. Lancet 364(9443), 1428-1434 (2004).
26. Homsy J, Dorsey G, Muhindo M et al. Protective efficacy of prolonged trimethoprim-sulfamethoxazole prophylaxis against malaria from birth to 4 years of age among HIV-exposed children in rural Uganda. Presented at: 19th Conference on Retroviruses and Opportunistic Infections. Washington, DC, USA, 5-8 March 2012.
27. Thera MA, Sehdev PS, Coulibaly D et al. Impact of trimethoprim- sulfamethoxazole prophylaxis on falciparum malaria infection and disease. J. Infect. Dis. 192(10), 1823-1829 (2005).
28. Grimwade K, Sturm AW, Nunn AJ, Mbatha D, Zungu D, Gilks CF. Effectiveness of cotrimoxazole prophylaxis on mortality in adults with tuberculosis in rural South Africa. AIDS 19(2), 163-168 (2005).
29. Prendergast A, Walker AS, Mulenga V, Chintu C, Gibb DM. Improved growth and anemia in HIV-infected African children taking cotrimoxazole prophylaxis. Clin. Infect. Dis. 52(7), 953-956 (2011).
30. Anglaret X, Chene G, Attia A et al. Early chemoprophylaxis with trimethoprim- sulphamethoxazole for HIV-1-infected adults in Abidjan, Cote d'Ivoire: A randomised trial. Cotrimo-CI Study Group. Lancet 353(9163), 1463-1468 (1999).
31. Wiktor SZ, Sassan-Morokro M, Grant AD et al. Efficacy of trimethoprim- sulphamethoxazole prophylaxis to decrease morbidity and mortality in HIV-1-infected patients with tuberculosis in Abidjan, Cote d'Ivoire: A randomised controlled trial. Lancet 353(9163), 1469-1475 (1999).
32. Mermin J, Ekwaru JP, Liechty CA et al. Effect of co-trimoxazole prophylaxis, antiretroviral therapy, and insecticide-treated bednets on the frequency of malaria in HIV-1-infected adults in Uganda: A prospective cohort study. Lancet 367(9518), 1256-1261 (2006).
33. Gasasira AF, Kamya MR, Ochong EO et al. Effect of trimethoprim- sulphamethoxazole on the riskof malaria in HIV-infected Ugandan children living in an area of widespread antifolate resistance. Malar. J. 9(1), 177 (2010).
34. Malamba S, Sandison T, Lule J et al. Plasmodium falciparum dihydrofolate reductase and dihyropteroate synthase mutations and the use of trimethoprim- sulfamethoxazole prophylaxis among persons infected with human immunodeficiency virus. Am. J. Trop. Med. Hyg. 82(5), 766-771 (2010).
35. Kayentao K, Kodio M, Newman RD et al. Comparison of intermittent preventive treatment with chemoprophylaxis for the prevention of malaria during pregnancy in Mali. J. Infect. Dis. 191(1), 109-116 (2005).
36. Njagi JK, Magnussen P, Estambale B, Ouma J, Mugo B. Prevention of anaemia in pregnancy using insecticide-treated bednets and sulfadoxine-pyrimethamine in a highly malarious area of Kenya: A randomized controlled trial. Trans. R. Soc. Trop. Med. Hyg. 97(3), 277-282 (2003).
37. Parise ME, Ayisi JG, Nahlen BL et al. Efficacy of sulfadoxine- pyrimethamine for prevention of placental malaria in an area of Kenya with a high prevalence of malaria and human immunodeficiency virus infection. Am. J. Trop. Med. Hyg. 59(5), 813-822 (1998).
38. Kapito-Tembo A, MeshnickSR, Van HensbroekMB, Phiri K, Fitzgerald M, Mwapasa V. Marked reduction in prevalence of malaria parasitemia and anemia in HIV-infected pregnant women taking cotrimoxazole with or without sulfadoxine-pyrimethamine intermittent preventive therapy during pregnancy in Malawi. J. Infect. Dis. 203(4), 464-472 (2011).
39. Newman PM, Wanzira H, Tumwine G et al. Placental malaria among HIV-infected and uninfected women receiving anti-folates in a high transmission area of Uganda. Malar. J. 8, 254 (2009).
40. Peters PJ, Thigpen MC, Parise ME, Newman RD. Safety and toxicity of sulfadoxine/pyrimethamine: Implications for malaria prevention in pregnancy using intermittent preventive treatment. Drug Saf. 30(6), 481-501 (2007).
41. Badri M, Ehrlich R, Wood R, Maartens G. Initiating co-trimoxazole prophylaxis in HIV-infected patients in Africa: An evaluation of the provisional WHO/UNAIDS recommendations. AIDS 15(9), 1143-1148 (2001).
42. Chintu C, Bhat GJ, Walker AS et al. Co-trimoxazole as prophylaxis against opportunistic infections in HIV-infected Zambian children (CHAP): A double-blind randomised placebo-controlled trial. Lancet 364(9448), 1865-1871 (2004).
43. Ledergerber B, Mocroft A, Reiss P et al. Discontinuation of secondary prophylaxis against Pneumocystis carinii pneumonia in patients with HIV infection who have a response to antiretroviral therapy. Eight European Study Groups. N. Engl. J. Med. 344(3), 168-174 (2001).
44. Weverling GJ, Mocroft A, Ledergerber B et al. Discontinuation of Pneumocystis carinii pneumonia prophylaxis after start of highly active antiretroviral therapy in HIV-1 infection. EuroSIDA Study Group. Lancet 353(9161), 1293-1298 (1999).
45. Campbell JD, Moore D, Degerman R et al. HIV-infected Ugandan adults taking antiretroviral therapy with CD4 counts >200 cells/muL who discontinue cotrimoxazole prophylaxis have increased riskof malaria and diarrhea. Clin. Infect. Dis. 54(8), 1204-1211 (2012).
46. Lowrance D, Makombe S, Harries A et al. Lower early mortality rates among patients receiving antiretroviral treatment at clinics offering cotrimoxazole prophylaxis in Malawi. J. Acquir. Immune Defic. Syndr. 46(1), 56-61 (2007).
47. Walker AS, Ford D, Gilks CF et al. Daily co-trimoxazole prophylaxis in severely immunosuppressed HIV-infected adults in Africa started on combination antiretroviral therapy: An observational analysis of the DART cohort. Lancet 375(9722), 1278-1286 (2010).
48. Kamya MR, Gasasira AF, Yeka A et al. Effect of HIV-1 infection on antimalarial treatment outcomes in Uganda: A population-based study. J. Infect. Dis. 193(1), 9-15 (2006).
49. Gasasira AF, Kamya MR, Achan J et al. High riskof neutropenia in HIV-infected children following treatment with artesunate plus amodiaquine for uncomplicated malaria in Uganda. Clin. Infect. Dis. 46(7), 985-991 (2008).
50. Khoo S, BackD, Winstanley P. The potential for interactions between antimalarial and antiretroviral drugs. AIDS 19(10), 995-1005 (2005).
51. Fellay J, Marzolini C, Decosterd L et al. Variations of CYP3A activity induced by antiretroviral treatment in HIV-1 infected patients. Eur. J. Clin. Pharmacol. 60(12), 865-873 (2005).
52. German P, Greenhouse B, Coates C et al. Hepatotoxicity due to a drug interaction between amodiaquine plus artesunate and efavirenz. Clin. Infect. Dis. 44(6), 889-891 (2007).
53. Kredo T, Mauff K, Van Der Walt JS et al. Interaction between artemether-lumefantrine and nevirapine-based antiretroviral therapy in HIV-1-infected patients. Antimicrob. Agents Chemother. 55(12), 5616-5623 (2011).
54. German P, Parikh S, Lawrence J et al. Lopinavir/ritonavir affects pharmacokinetic exposure of artemether/lumefantrine in HIV-uninfected healthy volunteers. J. Acquir. Immune Defic. Syndr. 51(4), 424-429 (2009).
55. Byakika-Kibwika P, Lamorde M, Okaba-Kayom V et al. Lopinavir/ritonavir significantly influences pharmacokinetic exposure of artemether/lumefantrine in HIV-infected Ugandan adults. J. Antimicrob. Chemother. 67(5), 1217-1223 (2012).
56. Achan J, Kakuru A, Ikilezi G et al. Significant reduction in riskof malaria among HIV-infected children receiving Lopinavir/ ritonavir-based ART vs. non nucleoside reverse transcriptase inhibitor-based ART. Presented at: 19th Conference on Retroviruses and Opportunistic Infections. Washington, DC, USA, 5-8 March 2012.
57. Parikh S, Gut J, Istvan E, Goldberg DE, Havlir DV, Rosenthal PJ. Antimalarial activity of human immunodeficiency virus type 1 protease inhibitors. Antimicrob. Agents Chemother. 49(7), 2983-2985 (2005).
58. Nsanzabana C, Rosenthal PJ. In vitro activity of antiretroviral drugs against Plasmodium falciparum. Antimicrob. Agents Chemother. 55(11), 5073-5077 (2011).
59. Soyinka JO, Onyeji CO, Omoruyi SI, Owolabi AR, Sarma PV, CookJM. Effects of concurrent administration of nevirapine on the disposition of quinine in healthy volunteers. J. Pharm. Pharmacol. 61(4), 439-443 (2009).
60. Soyinka JO, Onyeji CO, Omoruyi SI, Owolabi AR, Sarma PV, CookJM. Pharmacokinetic interactions between ritonavir and quinine in healthy volunteers following concurrent administration. Br. J. Clin. Pharmacol. 69(3), 262-270 (2010).
61. Van Geertruyden JP, Menten J, Colebunders R, KorenrompE, D'alessandro U. The impact of HIV-1 on the malaria parasite biomass in adults in sub-Saharan Africa contributes to the emergence of antimalarial drug resistance. Malar. J. 7, 134 (2008).
62. Ittarat W, Pickard AL, Rattanasinganchan P et al. Recrudescence in artesunate-treated patients with falciparum malaria is dependent on parasite burden not on parasite factors. Am. J. Trop. Med. Hyg. 68(2), 147-152 (2003).
63. Uriel A, Lewthwaite P. Malaria therapy in HIV: Drug interactions between nevirapine and quinine. Int. J. STD AIDS 22(12), 768 (2011).
64. Nankabirwa J, Brooker S, Staedke SG, Kamya M. School based malaria control: IMPACT of intermittent preventive treatment on malaria morbidity and cognitive function in Ugandan schoolchildren. Presented at: AMERICAN Society of Tropical Medicine and Hygiene (ASTMH) 60th Annual Meeting. Philadelphia, PA, USA, 4-8 December 2011.